Cargando…
Correction to: Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360153/ https://www.ncbi.nlm.nih.gov/pubmed/30726873 http://dx.doi.org/10.1093/annonc/mdy557 |
| _version_ | 1783559170729967616 |
|---|---|
| author | Chugh, R. Griffith, K.A. Davis, E.J. Thomas, D.G. Zavala, J.D. Metko, G. Brockstein, B. Undevia, S.D. Stadler, W.M. Schuetze, S.M. |
| author_facet | Chugh, R. Griffith, K.A. Davis, E.J. Thomas, D.G. Zavala, J.D. Metko, G. Brockstein, B. Undevia, S.D. Stadler, W.M. Schuetze, S.M. |
| author_sort | Chugh, R. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7360153 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-73601532020-07-18 Correction to: Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model Chugh, R. Griffith, K.A. Davis, E.J. Thomas, D.G. Zavala, J.D. Metko, G. Brockstein, B. Undevia, S.D. Stadler, W.M. Schuetze, S.M. Ann Oncol CORRIGENDA Oxford University Press 2019-08 2019-12-04 /pmc/articles/PMC7360153/ /pubmed/30726873 http://dx.doi.org/10.1093/annonc/mdy557 Text en © 2019 THE AUTHORS http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | CORRIGENDA Chugh, R. Griffith, K.A. Davis, E.J. Thomas, D.G. Zavala, J.D. Metko, G. Brockstein, B. Undevia, S.D. Stadler, W.M. Schuetze, S.M. Correction to: Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model |
| title | Correction to: Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model |
| title_full | Correction to: Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model |
| title_fullStr | Correction to: Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model |
| title_full_unstemmed | Correction to: Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model |
| title_short | Correction to: Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model |
| title_sort | correction to: doxorubicin plus the igf-1r antibody cixutumumab in soft tissue sarcoma: a phase i study using the tite-crm model |
| topic | CORRIGENDA |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360153/ https://www.ncbi.nlm.nih.gov/pubmed/30726873 http://dx.doi.org/10.1093/annonc/mdy557 |
| work_keys_str_mv | AT chughr correctiontodoxorubicinplustheigf1rantibodycixutumumabinsofttissuesarcomaaphaseistudyusingthetitecrmmodel AT griffithka correctiontodoxorubicinplustheigf1rantibodycixutumumabinsofttissuesarcomaaphaseistudyusingthetitecrmmodel AT davisej correctiontodoxorubicinplustheigf1rantibodycixutumumabinsofttissuesarcomaaphaseistudyusingthetitecrmmodel AT thomasdg correctiontodoxorubicinplustheigf1rantibodycixutumumabinsofttissuesarcomaaphaseistudyusingthetitecrmmodel AT zavalajd correctiontodoxorubicinplustheigf1rantibodycixutumumabinsofttissuesarcomaaphaseistudyusingthetitecrmmodel AT metkog correctiontodoxorubicinplustheigf1rantibodycixutumumabinsofttissuesarcomaaphaseistudyusingthetitecrmmodel AT brocksteinb correctiontodoxorubicinplustheigf1rantibodycixutumumabinsofttissuesarcomaaphaseistudyusingthetitecrmmodel AT undeviasd correctiontodoxorubicinplustheigf1rantibodycixutumumabinsofttissuesarcomaaphaseistudyusingthetitecrmmodel AT stadlerwm correctiontodoxorubicinplustheigf1rantibodycixutumumabinsofttissuesarcomaaphaseistudyusingthetitecrmmodel AT schuetzesm correctiontodoxorubicinplustheigf1rantibodycixutumumabinsofttissuesarcomaaphaseistudyusingthetitecrmmodel |